Abstract: Background Allergic bronchopulmonary aspergillosis (ABPA) is a severe complication in patients with cystic fibrosis (CF), resulting in deterioration of lung function and impairment of overall prognosis. Standard therapy consists of high dosage, long-term corticosteroid treatment. This carries the risk of serious side effects such as immune suppression, diabetes and osteoporosis. Antifungal drugs such as itraconazole may cause interactions with other drugs and drug levels need to be monitored. Omalizumab treatment has been tried in several case studies.
Methods: This is a retrospective analysis of patients with CF and ABPA receiving treatment with omalizumab from May 2014 to May 2015. A patient was treated at the Department of Paediatric Pulmonology of the king fasial special Hospital and research center the patient gave his written informed consent for retrospective analysis of their ABPA history. Diagnosis of CF in the patient was approved by cystic fibrosis transmembrane conductance regulator (CFTR) mutations.
Results/discussion: patient showed clinical and laboratory stability or even an improvement within the treatment and post-treatment observation period, although .Side effects of systemic steroids were reduced.
Conclusion: Omalizumab has the potential to be an additional and solitary treatment option in patients with CF and ABPA. Early onset treatment may be beneficial and patients with early stage of lung disease seem to be more benefit.
Keywords: ABPA; Aspergillus; cystic fibrosis; itraconazole; omalizumab.
Title: Omalizumab as New Modality of Treatment ABPA in Cystic Fibrosis Patient: Case Report
Author: Ibrahim Ali Al-Rashidi
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
